Hydrochlorothiazide/Lisinopril

氢氯噻嗪/赖诺普利

Report date: 2022/03/03 15:55:36

Base Information

Drug NameHydrochlorothiazide/Lisinopril
Drug Alias Name氢氯噻嗪赖诺普利Hydrochlorothiazide - lisinopril mixt赖诺普利氢氯噻嗪Lisinopril and HydrochlorothiazideHydrochlorothiazide and Lisinopril +[9] 
ClassificationSmall molecules
Mechanisms of ActionThiazide-sensitive sodium-chloride cotransporter inhibitorsAngiotensin-converting enzyme inhibitors
TargetsThiazide-sensitive sodium-chloride cotransporterAngiotensin-converting enzyme
Therapy Area/IndicationsEssential HypertensionHypertension
Global Approved IndicationsHypertension
Approved Indications in ChinaHypertension
Original Approved Country/TerritoryUnited States
Original Approved Date1989/02/16
Country/TerritoryUnited StatesMainland China
CombinationsYes HydrochlorothiazideLisinopril
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesMerck Sharp & Dohme Corp
China Registration ClassN/A

Develop Information

Active CompaniesAtnahs Pharma Uk LtdJiangsu Tasly Diyi Pharmaceutical Co LtdSichuan Shangrui Biomedicine Co Ltd
Inactive CompaniesMerck & Co Inc
Active IndicationsEssential HypertensionHypertension
Inactive IndicationsN/A

Other Information

ATC CodeC09BA03
Related LinksKEGG